Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.46 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.46 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.46 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761760 | 0.92 | KIF11 (0.62) | TRPV1TSHRLMNATYRKIF11 | |
| SCHEMBL22402545 | 0.85 | TRPV1 (0.46) | TRPV1TSHRLMNATYRKIF11 | |
| SCHEMBL25919597 | 0.85 | TRPV1 (0.46) | TRPV1TSHRLMNATYRKIF11 | |
| SCHEMBL19557869 | 0.85 | TRPV1 (0.46) | TRPV1TSHRLMNATYRKIF11 | |
| SCHEMBL4792792 | 0.85 | RAB9A (0.63) | TRPV1TSHRKIF11ALDH1A1 | |
| SCHEMBL24499138 | 0.85 | TRPV1 (0.46) | TRPV1TSHRLMNATYRKIF11 | |
| SCHEMBL677817 | 0.84 | ALDH1A1 (0.53) | TSHRKIF11ALDH1A1CES2CES1 | |
| SCHEMBL63468 | 0.83 | ALDH1A1 (0.67) | TSHRKIF11ALDH1A1CES2CES1 | |
| SCHEMBL424728 | 0.83 | TSHR (0.73) | TSHRLMNATYRKIF11ALDH1A1 | |
| SCHEMBL14703793 | 0.81 | ALDH1A1 (0.50) | TSHRKIF11ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 938 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240217902-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217902-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-6784327-B2 | ORGANIC COMPOUNDS HAVING HYDROGEN ATOMS, WHICH SERVE AS STARTING MATERIALS, ARE FLUORINATED USING IF5 | DAIKIN INDUSTRIES, LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20030176747-A1 | Process for the production of fluorinated organic compounds and fluorinating agents | DAIKIN INDUSTRIES, LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| CN-1436159-A | Processes for production of fluorinated organic compounds and fluorinating agent | DAIKIN IND LTD (JP) | 2003-08-13 | — | — | CN | disclosed |
| EP-1304316-A1 | PROCESSES FOR THE PRODUCTION OF FLUORINATED ORGANIC COMPOUNDS AND FLUORINATING AGENTS | Daikin Industries, Ltd. (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-0674651-B1 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5708001-A | TESTOSTERONE-5A-REDUCTASE INHIBITORS | GLAXO WELLCOME INC. (US) | 1998-01-13 | — | — | US | disclosed |
| CN-1095383-A | The 6-azepine androstenone that replaces | GLAXO INC (US) | 1994-11-23 | — | — | CN | disclosed |
| WO-1994014833-A2 | SUBSTITUTED 6-AZAANDROSTENONES | GLAXO WELLCOME INC. (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | TRPV1 2312/4885TSHR 2420/4885LMNA 3320/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | TRPV1 215/4885TSHR 818/4885LMNA 2850/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | TRPV1 2239/4885TSHR 4567/4885LMNA 1033/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | TRPV1 73/4885TSHR 3592/4885LMNA 1195/4885 |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | TRPV1 1513/4885TSHR 909/4885LMNA 1948/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | TRPV1 2815/4885TSHR 1793/4885LMNA 1590/4885 |
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | AOX1, AOC2, OSTC | TRPV1 1066/4885TSHR 4073/4885LMNA 3600/4885 |
| US-20240217902-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | EMC1, EMC2, AOC1 | TRPV1 2042/4885TSHR 3926/4885LMNA 2644/4885 |
| US-20030176747-A1 | Process for the production of fluorinated organic compounds and fluorinating agents | PFAS, AFF4, AFF1 | TRPV1 3861/4885TSHR 2577/4885LMNA 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.